/** slug: pi-q1fy27 */

PI Industries Q1 FY27: Profit Softens, Platforms Build for the Next Cycle

PI Industries started FY27 with a softer quarter on reported profitability, as the global agrochemical down-cycle continued to weigh on exports and input costs stayed elevated amid geopolitical disruptions. For Q1 FY27 (quarter ended June 30, 2026), consolidated revenue came in at INR 17,023 million, down 10 percent year on year. EBITDA declined 29 percent to INR 3,693 million and PAT declined 39 percent to INR 2,442 million. The company reported a gross margin of 57 percent and an EBITDA margin of 22 percent.

The quarter, however, was not a single-thread story. Domestic agri held up better than exports, biologicals showed sharp growth, and the company continued to fund long-gestation bets across global biologicals, pharma CRDMO and electronic and specialty chemicals. Management also emphasized its balance sheet strength and working capital improvements, positioning these as buffers to invest through volatility.

Financial performance: Exports remain the swing factor

The consolidated revenue decline was primarily driven by weakness in exports. Export revenue fell to INR 13,542 million in Q1 FY27 from INR 15,620 million in Q1 FY26. Management attributed this to softer demand across the global agrochemical industry, with volume down about 8 percent and a broader pricing and demand pressure across the value chain.

Domestic revenue was comparatively stable at INR 3,481 million versus INR 3,385 million a year ago. The company noted domestic volumes grew around 12 percent, but pricing remained under pressure. The delayed and uneven monsoon also resulted in partial postponement of sales in the quarter.

Despite the operating headwinds, PI Industries highlighted that it commercialized three new molecules in exports during Q1 FY27. On the call, management also referenced an order book of USD 1.2 billion and contract assets of around INR 750 crore for June 2026, both of which are useful indicators of medium-term execution visibility.

Domestic business: Volume growth led by biologicals

PI Industries’ domestic business delivered a steady quarter in revenue terms even as pricing stayed soft. Management’s commentary pointed to two simultaneous forces: weather-related disruption in the early part of the season and the company’s effort to defend and build market share through differentiated products.

A key highlight in the investor deck was the strong growth in biologicals. Domestic biologicals grew 50 percent plus year on year in Q1 FY27. Management framed biologicals as a long-term strategic focus, while acknowledging that near-term performance across the broader domestic market was affected by delayed sowing and uneven rainfall.

The company also reiterated its strength in domestic distribution reach, citing 25 stock points, 15,000 plus distributors and 100,000 plus retail points. In the concall, management highlighted flagship domestic brands such as Nominee Gold, Brofreya and Biovita as examples of products that have maintained leadership positions.

Global biologicals: Peptide platform steps into the field

A substantial portion of the strategic narrative in both the presentation and the transcript focused on PI’s global biologicals platform, particularly peptide-based products. The deck notes that the second-generation product Harpinαβ has been commercialized in more than 25 countries. It also highlights a nematicide peptide product that is positioned as performing at par with leading chemical nematicides.

On the call, management shared a concrete reference point for market sizing. In Brazil, the nematicide market is estimated at roughly USD 750 million. PI’s product is registered in Brazil, Mexico and the US, with the US launch described as underway. Management stated that farmers tested the product across about 5 million hectares in Brazil and emphasized that its key differentiation is flexibility, with application possible through seed treatment, in-furrow soil application and foliar use.

At the same time, management introduced a practical note of caution: shifting farmer habits and establishing a new concept such as foliar nematode management takes time. This suggests that while the product has a strong differentiation narrative, adoption and scaling are likely to be measured over multiple seasons.

PI Health Sciences: Building a CRDMO platform with early-stage volatility

PI Health Sciences (PIHS), the company’s pharma initiative, reported a weaker quarter on a small base. PIHS revenue declined 25 percent year on year to INR 542 million in Q1 FY27. PBT loss, post intercompany eliminations, stood at INR 617 million.

Management attributed the revenue decline largely to customer order phasing and delivery schedules. The company’s stated direction remains the build-up of a differentiated CRDMO platform, supported by capability enhancement in Italy and India.

Key capability updates included renewal of AIFA GMP certification for the Lodi site in Italy and a QC lab GMP certification at the same facility. The deck also states capex of around INR 233 million for CRDMO capacity expansion, QC and kilolab facilities in Lodi and a biology lab in Hyderabad.

Management acknowledged that volatility is higher at the current scale, and that standard deviation should reduce as the customer base and portfolio widen over time.

Capital allocation and balance sheet: Cash cushion plus working capital gains

PI Industries continued to emphasize balance sheet resilience. The deck states net cash balance increased to INR 37,939 million as of June 2026 and the company remains effectively net debt-free, with a debt-to-equity ratio of 0.02.

Operationally, working capital efficiency improved. Net working capital days reduced by 19 days to 120 days in June 2026, aided by a reduction in receivables days and an increase in payables days. The company reported cash flow from operating activities of INR 6,395 million in Q1 FY27.

The company also maintained its capex momentum. Total capex for Q1 FY27 was INR 2,685 million. In the concall, management guided for FY27 capex of INR 700 to 800 crore and indicated this would be allocated across existing manufacturing assets, new verticals and innovation-led initiatives.

Outlook: Lower single digit growth guidance, second-half export recovery expected

Management maintained a cautious but positive outlook. In the concall, management reiterated that the FY27 revenue growth trajectory is expected to be positive in the lower single digits, subject to how the industry cycle evolves. The company also stated an expectation that FY27 should be better than FY26, driven by recovery in exports in the second half.

On taxation, management guided for an effective tax rate of around 24 percent for FY27.

The longer-term narrative remained centered on continuing investments across new business lines and product platforms, including new launches in exports and the ramp-up of global biologicals. The company also referenced progress on its first NCE, Pioxaniliprole, which management said is expected to launch in India within FY27 subject to regulatory approvals.

Key takeaways

Q1 FY27 reflected a weak profitability print driven by export softness and cost pressures, but it also showed signs of platform building. Domestic biologicals growth, continued product commercialization in exports, and heavy investment into global biologicals and pharma CRDMO illustrate that the company is prioritizing long-cycle capability creation.

For investors tracking PI Industries, the near-term debate is likely to remain centered on export recovery and margin stability. The medium-term debate shifts to whether the biologicals and pharma platforms can scale meaningfully after an investment-heavy phase, while the balance sheet and working capital improvements provide the cushion to keep funding those bets through a volatile cycle.